» Articles » PMID: 35159385

Targeting Breast Cancer and Their Stem Cell Population Through AMPK Activation: Novel Insights

Overview
Journal Cells
Publisher MDPI
Date 2022 Feb 15
PMID 35159385
Authors
Affiliations
Soon will be listed here.
Abstract

Despite some significant advancements, breast cancer has become the most prevalent cancer in the world. One of the main reasons for failure in treatment and metastasis has been attributed to the presence of cancer initiating cells-cancer stem cells. Consequently, research is now being focussed on targeting cancer cells along with their stem cell population. Non-oncology drugs are gaining increasing attention for their potent anticancer activities. Metformin, a drug commonly used to treat type 2 diabetes, is the best example in this regard. It exerts its therapeutic action by activating 5' adenosine monophosphate-activated protein kinase (AMPK). Activated AMPK subsequently phosphorylates and targets several cellular pathways involved in cell growth and proliferation and the maintenance of stem-like properties of cancer stem cells. Therefore, AMPK is emerging as a target of choice for developing effective anticancer drugs. Vanadium compounds are well-known PTP inhibitors and AMPK activators. They find extensive applications in treatment of diabetes and obesity via PTP1B inhibition and AMPK-mediated inhibition of adipogenesis. However, their role in targeting cancer stem cells has not been explored yet. This review is an attempt to establish the applications of insulin mimetic vanadium compounds for the treatment of breast cancer by AMPK activation and PTP1B inhibition pathways.

Citing Articles

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.

Wang J, Shao F, Yu Q, Ye L, Wusiman D, Wu R Research (Wash D C). 2025; 8:0612.

PMID: 40046513 PMC: 11880593. DOI: 10.34133/research.0612.


CircWHSC1 (CircNSD2): A Novel Circular RNA in Multiple Cancers.

Zhang X, Yuan Y, Wang X, Wang H, Zhang L, He J Clin Med Insights Oncol. 2024; 18:11795549241254781.

PMID: 38855031 PMC: 11159554. DOI: 10.1177/11795549241254781.


Repurposing Therapeutic Drugs Complexed to Vanadium in Cancer.

De Sousa-Coelho A, Fraqueza G, Aureliano M Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38275998 PMC: 10819319. DOI: 10.3390/ph17010012.


The role of AMPK in macrophage metabolism, function and polarisation.

Cui Y, Chen J, Zhang Z, Shi H, Sun W, Yi Q J Transl Med. 2023; 21(1):892.

PMID: 38066566 PMC: 10709986. DOI: 10.1186/s12967-023-04772-6.


Targeting Breast Cancer: An Overlook on Current Strategies.

Iacopetta D, Ceramella J, Baldino N, Sinicropi M, Catalano A Int J Mol Sci. 2023; 24(4).

PMID: 36835056 PMC: 9959993. DOI: 10.3390/ijms24043643.


References
1.
Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z . AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013; 17(1):113-24. PMC: 3545102. DOI: 10.1016/j.cmet.2012.12.001. View

2.
Liberti M, Locasale J . The Warburg Effect: How Does it Benefit Cancer Cells?. Trends Biochem Sci. 2016; 41(3):211-218. PMC: 4783224. DOI: 10.1016/j.tibs.2015.12.001. View

3.
Ito Y, Hsu M, Bettaieb A, Koike S, Mello A, Calvo-Rubio M . Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury. Metabolism. 2017; 76:56-69. PMC: 5690491. DOI: 10.1016/j.metabol.2017.07.009. View

4.
Liao S, Li J, Yu L, Sun S . Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer. J Zhejiang Univ Sci B. 2017; 18(4):334-342. PMC: 5394098. DOI: 10.1631/jzus.B1600184. View

5.
Luo J, Hou Y, Xie M, Ma W, Shi D, Jiang B . CYC31, A Natural Bromophenol PTP1B Inhibitor, Activates Insulin Signaling and Improves Long Chain-Fatty Acid Oxidation in C2C12 Myotubes. Mar Drugs. 2020; 18(5). PMC: 7281472. DOI: 10.3390/md18050267. View